New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk
New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk.
This is a case of labeling catching up with the evidence.
Bisphosphonates persist in the bones for years, so 3 to 5 years of therapy is enough for many patients.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote